Lead sponsor
Vanda Pharmaceuticals
2 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
2
Trials led
1
Active
404
Total enrollment
11
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
1
Phase 3
1
Trials by status
Recruiting
1
Completed
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseBMI 25-40Ph 3Recruiting280
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist UseBMI 25-40Ph 2Completed124